Online citations, reference lists, and bibliographies.

A Randomized Comparison Of A Sirolimus-eluting Stent With A Standard Stent For Coronary Revascularization.

M Morice, Patrick W. Serruys, Jose Eduardo M. Sousa, Jean Fajadet, Ernesto Ban Hayashi, Marco Antonio Perin, Antonio Colombo, Gerhard Schuler, Paul Barragan, Giulio Guagliumi, Ferenc Molnár, Robert Falotico
Published 2002 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND The need for repeated treatment of restenosis of a treated vessel remains the main limitation of percutaneous coronary revascularization. Because sirolimus (rapamycin) inhibits the proliferation of lymphocytes and smooth-muscle cells, we compared a sirolimus-eluting stent with a standard uncoated stent in patients with angina pectoris. METHODS We performed a randomized, double-blind trial to compare the two types of stents for revascularization of single, primary lesions in native coronary arteries. The trial included 238 patients at 19 medical centers. The primary end point was in-stent late luminal loss (the difference between the minimal luminal diameter immediately after the procedure and the diameter at six months). Secondary end points included the percentage of in-stent stenosis of the luminal diameter and the rate of restenosis (luminal narrowing of 50 percent or more). We also analyzed a composite clinical end point consisting of death, myocardial infarction, and percutaneous or surgical revascularization at 1, 6, and 12 months. RESULTS At six months, the degree of neointimal proliferation, manifested as the mean (+/-SD) late luminal loss, was significantly lower in the sirolimus-stent group (-0.01+/-0.33 mm) than in the standard-stent group (0.80+/-0.53 mm, P<0.001). None of the patients in the sirolimus-stent group, as compared with 26.6 percent of those in the standard-stent group, had restenosis of 50 percent or more of the luminal diameter (P<0.001). There were no episodes of stent thrombosis. During a follow-up period of up to one year, the overall rate of major cardiac events was 5.8 percent in the sirolimus-stent group and 28.8 percent in the standard-stent group (P<0.001). The difference was due entirely to a higher rate of revascularization of the target vessel in the standard-stent group. CONCLUSIONS As compared with a standard coronary stent, a sirolimus-eluting stent shows considerable promise for the prevention of neointimal proliferation, restenosis, and associated clinical events.



This paper is referenced by
10.1532/HSF98.20051107
Comparison between multivessel stenting with drug eluting to the LAD and bilateral internal thoracic artery grafting.
Itzhak Herz (2006)
10.1093/eurheartj/ehm197
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
Pilar Jiménez-Quevedo (2007)
10.1093/eurheartj/ehl499
Variability in response to clopidogrel: where is the threshold for 'low response'?
Aradi Dániel (2007)
10.1161/CIRCULATIONAHA.114.013279
Are at least 12 months of dual antiplatelet therapy needed for all patients with drug-eluting stents? All patients with drug-eluting stents need at least 12 months of dual antiplatelet therapy.
Sorin J. Brener (2015)
10.1016/j.jvs.2014.03.235
Infrainguinal angioplasty with drug-eluting stents and balloons.
Ludovic Canaud (2014)
10.1161/01.CIR.0000094405.21583.7C
Indications for Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention in Chronic Stable Angina: Review of the Evidence and Methodological Considerations
Charanjit S. Rihal (2003)
10.1001/jama.295.11.1264
Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial.
David R Holmes (2006)
10.1016/j.jacc.2013.07.047
Ready for a marathon, not a sprint: renal denervation therapy for treatment-resistant hypertension.
David E Kandzari (2013)
10.1016/j.ijcard.2013.07.154
Phospholipase A2 expression in coronary thrombus is increased in patients with recurrent cardiac events after acute myocardial infarction.
Soichiro Takahashi (2013)
CURRENT STATUS AND FUTURE PERSPECTIVES ON DRUG-ELUTING BIORESORBABLE CORONARY SCAFFOLDS: WILL THE PARADIGM OF PCI SHIFT?
Alfonso Ielasi (2014)
10.1002/ccd.28698
Stent selection among patients with chronic kidney disease: Results from the NCDR CathPCI Registry.
Daniel A Feldman (2020)
10.21427/D7G31Z
Sequential Structural and Fluid Dynamics Analysis of Balloon-Expandable Coronary Stents.
David D Martin (2013)
10.1111/j.1540-8183.2004.04079.x
Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies?
S. K. Silber (2004)
10.1016/S1279-7960(06)75549-8
Conduite à tenir devant un patient porteur d’une endoprothèse coronaire devant être anesthésié et opéré
P. Staat (2006)
10.1096/fj.05-4981com
A20, a modulator of smooth muscle cell proliferation and apoptosis, prevents and induces regression of neointimal hyperplasia.
Virendra I. Patel (2006)
10.1016/S0300-8932(04)77238-3
Resultados inmediatos y a largo plazo de la angioplastia con stent del tronco común
Vicens Martí (2004)
10.4244/EIJV2I4A78
Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial.
Bernard Chevalier (2007)
10.4414/smw.2011.13263
Drug-eluting coronary stents in clinical practice: lessons from the «BAsel Stent Kosten-Effektivitäts Trials» (BASKET). A review of the BASKET trials.
Matthias Emil Pfisterer (2011)
10.4149/BLL_2012_001
Tacrolimus inhibits intimal hyperplasia in arterialised veins in rats.
Martin Varga (2012)
Differences between Early, Intermediate and Late Angioplasty following Coronary Artery Bypass Grafting
Eng Shiong (2018)
Multivessel Coronary Artery Disease Treated with Drug-Eluting Stents
Vassilis Spanos (2004)
Long Term Follow-up after Drug-eluting Stent Implantation and Early Experience with Endothelial Progenitor Cell Capture Stent
Jiro Aoki (2006)
Novel percutaneous therapies for complex coronary atherosclerosis
Chourmouzios A. Arampatzis (2004)
10.1016/j.ehj.2003.10.012
Intravascular ultrasound evaluation after sirolimus eluting stent implantation for de novo and in-stent restenosis lesions.
Muzaffer Değertekin (2004)
PHARMACO-MECHANICAL APPROACH TO CAD Stent Design : Implications for Restenosis
Dougal Mcclean (2002)
Der Einsatz von Unfraktioniertem Heparin in der Perkutanen Transluminalen Angioplastie. Die Aktivierte Gerinnungszeit (ACT) als Kontrollparameter.
Tobias Reuter (2008)
10.4414/fms.2003.04746
Cardiologie: Plus de vie grâce à l'ICD
Hans Rickli (2003)
Current status of drug-eluting stents
Sunghwan Kim (2008)
10.1016/j.atherosclerosis.2009.07.040
Tacrolimus-eluting stent inhibits neointimal hyperplasia via calcineurin/NFAT signaling in porcine coronary artery model.
Narisato Hamada (2010)
10.1016/j.jconrel.2020.02.012
Microneedle drug eluting balloon for enhanced drug delivery to vascular tissue.
KangJu Lee (2020)
10.1371/journal.pone.0224026
Experimentally validated simulation of coronary stents considering different dogboning ratios and asymmetric stent positioning
Lisa Wiesent (2019)
10.1016/S1885-5857(07)60133-9
[Janus tacrolimus-eluting carbostent. Immediate and medium-term clinical results].
Julio García-Tejada (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar